• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    What IPG Photonics (IPGP)'s Patent Setback and CROSSBOW HEL Push Mean for Shareholders

    Simply Wall St·03/27/2026 03:18:32
    Listen to the news
    • Earlier this month, IPG Photonics reported an unfavorable patent ruling from the Unified Patent Court in Düsseldorf affecting certain adjustable mode beam lasers in Germany, France and Italy, while also confirming contingency support for impacted customers and reiterating that less than 1% of total sales are involved.
    • At the same time, IPG is pushing into defense markets, with IPG Defense showcasing its CROSSBOW HEL counter‑UAS laser systems at the AUSA Global Force Symposium in Huntsville, underscoring how legal setbacks in parts of its industrial portfolio are occurring alongside efforts to broaden its role in directed‑energy applications.
    • We’ll now examine how the expanding CROSSBOW HEL defense showcase could reshape IPG Photonics’ investment narrative around growth, margins, and diversification.

    We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

    IPG Photonics Investment Narrative Recap

    To own IPG Photonics, you need to believe its fiber laser technology can translate into durable earnings and stronger margins, despite past revenue softness and cost pressures. Near term, the key catalyst is whether newer applications like defense and laser curing can scale enough to support profitability, while the biggest risk remains legal and competitive pressure on its core industrial lasers. The recent UPC rulings look limited in sales impact but keep legal risk firmly in focus.

    Against that backdrop, IPG Defense exhibiting its CROSSBOW HEL counter UAS systems at AUSA in Huntsville highlights how defense is becoming a more visible part of the story. This ties directly into the idea that higher value advanced applications could improve margins and lessen dependence on slower industrial materials processing, even as investors weigh execution risk and the still nascent size of these newer markets.

    Yet behind the excitement around CROSSBOW and advanced applications, investors should be aware of the ongoing tariff and geopolitical pressures that could...

    Read the full narrative on IPG Photonics (it's free!)

    IPG Photonics' narrative projects $1.2 billion revenue and $133.9 million earnings by 2028. This requires 8.1% yearly revenue growth and a $349.3 million earnings increase from -$215.4 million today.

    Uncover how IPG Photonics' forecasts yield a $96.08 fair value, a 19% downside to its current price.

    Exploring Other Perspectives

    IPGP 1-Year Stock Price Chart
    IPGP 1-Year Stock Price Chart

    Some of the most optimistic analysts were expecting revenue around US$1.2 billion and earnings near US$169 million by 2028, so compared with today’s legal and defense headlines you can see how their faster growth and margin story could be challenged or reinforced depending on how CROSSBOW and the UPC cases evolve.

    Explore 2 other fair value estimates on IPG Photonics - why the stock might be worth 19% less than the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Want Some Alternatives?

    Opportunities like this don't last. These are today's most promising picks. Check them out now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.